Login / Register

Username:


Password: [Lost?]



New User? Click here for your FREE subscription



Mental Health Professionals
Mental Health Professionals Mental Health Professionals

Follow Us


NEWS-Line on Twitter NEWS-Line on Facebook NEWS-Line on Google+ NEWS-Line on LinkedIn NEWS-Line on Pinterest


Mental Health Conferences &
Educational Opportunities




March 30 - April 3

SLP2B 2020 Conference

XceptionalEd

April 21 - 24

Atlanta CME Conference

Skin, Bones, Hearts & Private Parts

June 9 - 12

Destin CME Conference

Skin, Bones, Hearts & Private Parts

June 23 - 28

2020 AANP National Conference

American Association of Nurse Practitioners

July 9 - 12

2020 National Nurse Practitioner Symposium

National Nurse Practitioner Symposium

More Events

NeuroRx Drug for Suicidal Bipolar Depression Receives Notification of Patent Allowance | NEWS-Line for Mental Health Professionals
 


NeuroRx Drug for Suicidal Bipolar Depression Receives Notification of Patent Allowance


Source:

NeuroRx, Inc announced that it has received a notice of patent allowance covering the Composition of Matter for its drug NRX-101, which targets suicidal bipolar depression, an unmet medical need that results in the death of more than 25,000 Americans each year.

The allowance is based on US Patent Application 15/987,932 entitled: Composition and Method for Treatment of Depression and Psychosis in Humans. The inventor, Prof. Daniel Javitt, Ph.D., M.D., is co-founder of NeuroRx and was among the first to report the role of the NMDA receptor in psychiatric disease.

NRX-101, an NMDA-targeted antidepressant, is a fixed-dose combination of D-cycloserine and lurasidone and was awarded Fast Track and Breakthrough Therapy Designation by the US FDA. The drug is currently undergoing phase 3 clinical trials under an FDA Special Protocol Agreement (ClinicalTrials.gov Identifier: NCT03396068).

NeuroRx's Chairman and CEO, Dr. Jonathan Javitt, and Chief Commercial Officer, Mr. Robert Besthof, will be attending the upcoming JP Morgan Healthcare Conference in San Francisco, CA.

About NeuroRx, Inc.:

NeuroRx draws upon 30 years of basic science and clinical expertise in the role of N-methyl-D- aspartate (NMDA), a receptor that regulates human thought processes, particularly depression and suicidality. The company is privately funded and led by former senior executives of Johnson & Johnson, BMS, Eli Lilly, Pfizer, and Sunovion. NeuroRx's Board of Directors and Advisors includes Hon. Sherry Glied, former Assistant Secretary, U.S. Dept. of Health and Human Services; Mr. Chaim Hurvitz, former President of the Teva International Group, Lt. Gen. HR McMaster, the 23rd National Security Advisor, Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, Judge Abraham Sofaer, and Daniel Troy, former Chief Counsel, U.S. Food and Drug Administration.

About NRX-101

NRX-101 is designed to address suicidal bipolar depression for which there is no currently approved drug and for which the only FDA-approved treatment remains electroconvulsive therapy (ECT). NRX-101 is a patented, oral, fixed-dose combination of D-cycloserine, an N- methyl-D-aspartate (NMDA) receptor modulator, and lurasidone, which has D2/5-HT2a receptor antagonist activity. The combination has shown statistically-significant reduction in both depression and suicidal ideation in phase 2 studies and was awarded FDA Breakthrough Therapy Designation and Fast Track Designation. A pivotal phase 3 study is ongoing under an FDA Special Protocol Agreement that targets patients with Severe Bipolar Depression and Acute Suicidal Ideation.

Learn more at www.NeuroRxpharma.com

SOURCE NeuroRx, Inc.






Share This!


Mental Health Jobs






*Unique Non-Traditional Nursing Opportunity*,

Bergens Promise Inc
Bergen County, New Jersey

Bilingual Licensed Clinician for Cares PHP

CFG Health Network
Trenton, New Jersey

Outpatient Therapists - Psychologists, Licensed Clinical Social Workers (LCSW) or Licensed Professional Counselors (LPC).

CFG Health Network
Marlton, New Jersey

SPEECH/LANGUAGE PATHOLOGISTS - Preschool Special Education Program

Shield Institute
Bronx, New York

Speech-Language Pathologists - $1000 Sign-On Bonus

UCP of Central Arizona
Central, Arizona

Medical Social Worker, MSW, Home Health Care

BAYADA Home Health Care
Columbia, MD

More Jobs
(Dismiss) Thank you for visiting NEWS-Line! Please sign up, login, or follow us on your favorite social networks
to receive custom tailored eNews, job listings, and educational opportunities for your specific profession.